COMP <GO>
VRDN vs MBX // GROSS PROFIT MARGIN
Viridian Therapeutics Inc. (NASDAQ) VS. MBX Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: VRDN 2
— MBX 2
■ METRIC PARITY
LAST: $24.80 (+2.18%) • MKT CAP: $2.81B
gross-margins
—
LAST: $54.54 (+0.70%) • MKT CAP: $2.63B
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRDN VS. MBX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VRDN | MBX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -26.40% | -8.60 | MBX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.85% | -3.12% | -6.73 | MBX | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.8 | 53.8 | +16.02 | VRDN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.81B | $2.63B | $183.0M | VRDN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VRDN REV | MBX REV | VRDN GROSS % | MBX GROSS % | VRDN FCF | MBX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$276.9M | -$81.9M |
| FY 2024 | $0 | $0 | — | — | -$232.8M | -$55.6M |
| FY 2023 | $0 | $0 | — | — | -$184.2M | -$32.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRDN // BETA —
MBX // BETA —